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	 Stability	 evaluation	 of	 the	 drug	 substance	 is	 an	 integral	 part	 of	 the	 systematic	 approach	 to
stability	 studies.	 Hence,	 three	 simple,	 sensitive	 and	 precise	 methods	 depending	 on	 two
different	techniques	as	UV	spectrophotometry	and	chromatography	were	adopted	for	the	task
of	 stability	 indicating	 determination	 of	 sertaconazole	 (SER)	 in	 presence	 of	 its	 acidic
degradation	 products.	 The	 first	method	 is	 Zero‐crossing	 first	 derivative	 (1D)	 spectrophoto‐
metric	one,	which	allows	the	determination	of	SER	over	a	concentration	range	of	4‐64	µg/mL
at	290	nm	with	mean	percentage	 recoveries	99.77±0.781.	While	 first‐derivative	of	 the	 ratio
spectra	 (1DR)	 is	 the	method	of	choice	 for	determination	of	pure	SER	at	a	maximum	300	nm
and	 at	 a	 trough	 304	 nm,	with	mean	 percentage	 recoveries	 99.98±0.720	 and	 100.46±0.640,
respectively.	The	third	developed	HPLC	method	used	a	RP‐ZORBAX	C18	column	(5	μm	particle
size,	 250×4.6	mm;	 id)	with	 isocratic	 elution.	 The	mobile	 phase	was	methanol:	 0.2%	 formic
acid	aqueous	solution	(75:25,	v:v);	pH	=	3.5	at	the	flow	rate	of	1.0	mL/min,	with	UV	detection
at	 260	 nm.	 The	 method	 could	 determine	 SER	 in	 the	 range	 of	 0.8‐40	µg/mL	with	 a	 mean
percentage	 recovery	 of	 99.65±0.630.	 The	 developed	 methods	 were	 succeeded	 in	 the
determination	 of	 SER	 in	 bulk	 powder,	 pharmaceutical	 dosage	 forms	 and	 in	 presence	 of	 its
acidic	 degradation	 products.	 The	 results	 obtained	 were	 validated	 in	 compliance	 with	 ICH
guidelines	and	compared	statistically	with	each	other	and	to	those	of	the	official	method	in	the
British	Pharmacopoeia	regarding	both	accuracy	and	precision.	
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1.	Introduction	
	
Sertaconazole	(SER);	1‐[2‐[(7‐chloro‐1‐benzothiophen‐3‐yl)	
methoxy]‐2‐(2,4‐dichlorophenyl)ethyl]‐1H‐imidazole	 (Figure	
1)	is	a	broad	spectrum	antifungal	agent	[1].	Sertaco‐nazole	is	a	
member	 of	 imidazole	 antifungal	 group	 used	 topically	 as	 the	
nitrate	 with	 excellent	 activity	 against	 yeasts,	 dermatophytes	
and	opportunistic	fungi	[2].	It	is	believed	that	it	acts	primarily	
by	inhibiting	the	synthesis	of	ergosterol	through	inhibiting	the	
14α‐demethylase	enzyme.	Ergosterol	 is	 an	 important	 compo‐
nent	of	the	cell	membrane	of	fungi,	the	lack	of	this	component	
leads	 cell	 injury	mainly	 by	 leakage	 of	 cellular	 constituents	 in	
the	cytoplasm	from	the	cell.	
In	addition	 to	 this	antifungal	efficacy,	 it	has	a	good	safety	
profile,	 sustained	 cutaneous	 retention,	 and	 low	 systemic	
absorption,	 all	 of	which	make	 it	 ideal	 for	 topical	 applications	
[3].	 In	 fact,	 both	 British	 and	 European	 pharmacopeias	
described	 non‐aqueous	 titrations	 for	 its	 determination	 [4,5]	
and	till	now,	few	methods	have	been	reported	for	the	analysis	
of	SER	as	spectrophotometry	[6],	spectrofluorimetry	[7],	liquid	
chromatography	 [8‐10],	 TLC	 [7],	 and	 capillary	 zone	 electro‐
phoresis	[11].		
The	 aim	 of	 this	 presented	 work	 is	 to	 develop	 different	
analytical	 techniques	 as	 stability	 indicating	 methods	 for	
determination	of	antifungal	drug;	sertaconazole	either	in	pure	
form	or	in	presence	of	its	acidic	degradation	products	without	
prior	physical	separation	steps.	The	proposed	methods	can	be	
successfully	 applied	 in	 assay	 of	 the	 cited	 drug	 in	 pharma‐
ceutical	 formulation	 as	 a	 routine	 work	 analysis	 in	 quality	
control	labs.	
	
	
	
Figure	1.	Chemical	structure	of	intact	sertaconazole.
	
382	 Alamein	/	European	Journal	of	Chemistry	6	(4)	(2015)	381‐386	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
The	absorption	spectra	of	the	samples	were	recorded	by	a	
double	 beam	 UV‐VIS	 spectrophotometer	 (UV‐1800,	 Japan)	
connected	 to	 IBM	 compatible	 computer	 with	 the	 bundled	
software	(UV	probe	software	version	2.32,	Shimadzu)	and	the	
spectral	bandwidth	was	0.1	nm.	The	absorption	spectra	were	
carried	out	using	1	cm	quartz	cells.	HPLC	was	performed	using	
a	 1200	 Series	 chromatograph	 equipped	 with	 a	 quaternary	
pump	(No.	G‐1311A),	UV	variable	wavelength	detector,	20	mL	
injector	 loop,	 and	manual	 injector	Model	No.	 7725	 I	 (Agilent	
Technologies,	 Waldbronn,	 Germany).	 The	 pH	 meter	 was	 a	
digital	 pH/MV/TEMP/ATC	 meter,	 Model	 5005	 (Jenco	
Instruments,	San	Diego,	CA).	The	GC‐Mass	spectrometer	was	a	
Shimadzu	 QP‐2010	 (Kyoto,	 Japan),	 which	 was	 operated	 on	
electron	impact	(EI)	mode	at	70	eV.	
	
2.2.	Materials	and	reagents	
	
Pure	samples	of	sertaconazole	nitrate	was	kindly	supplied	
by	 October	 Pharma	 Pharmaceutical	 Co.,	 Egypt.	 The	 purity	 of	
the	 samples	was	 found	 to	 be	 100.52±0.427,	 according	 to	 the	
official	 non	 aqueous	 method	 in	 British	 Pharmacopoeia	 [4].	
Dermofix®cream,	Batch	No.	030409	 labeled	 to	contain	20	mg	
of	 sertaconazole	 nitrate	 per	 each	 one	 gram	 of	 cream	 and	
Dermofix	 ®powder,	 Batch	 No.	 0080909,	 each	 one	 gram	 is	
claimed	to	contain	20	mg	of	sertaconazole	nitrate.	Creams	and	
powders	 are	 manufactured	 by	 October	 Pharma‐Egypt	 under	
License	 of	 Ferrer	 International‐Barcelona,	 Spain.	 Degraded	
sample	 was	 prepared	 by	 the	 application	 of	 accelerated	 acid	
stress	 condition	 to	 the	 intact	 sertaconazole	 nitrate.	 After	
complete	 degradation,	 the	 major	 degradation	 product	 was	
subjected	 to	 GC/MS	 spectroscopy	 for	 structure	 elucidation.	
Methanol	 and	 formic	 acid	 were	 HPLC	 grade;	 E.	 Merck	
(Darmstadt,	 Germany).	 Concentrated	 hydrochloric	 acid	 and	
sodium	 hydroxide	 were	 purchased	 from	 El‐Nasr	 Pharma‐
ceutical	 Chemicals	 Co.,	 Abu‐Zabaal,	 Cairo,	 Egypt.	 All	 chemical	
used	were	of	 the	 analytical	 grade	 and	 other	 organic	 solvents	
were	of	spectroscopic	grade.	
	
2.3.	Standard	solution	for	the	intact	drug	(1	mg/mL)		
	
The	 intact	 sertaconazole	 pure	 sample	 (0.05	 g)	 was	
accurately	 weighed	 and	 transferred	 into	 a	 50	mL	measuring	
flask	and	volume	was	completed	with	methanol.	Sertaconazole	
working	solution	(0.08	mg/mL)	was	prepared	by	transferring	
8	mL	 of	 the	 standard	 stock	 solution	 into	 100	mL	 volumetric	
flask	and	then	the	volume	was	made	up	with	methanol.	
		
2.4.	Standard	solution	for	the	acidic	degradation	products	
(1	mg/mL)	
	
The	 pure	 sertaconazole	 powder	 (0.05	 g)	 was	 accurately	
weighed	 and	 transferred	 to	 a	 100	mL	 round	 bottomed	 flask.	
Then,	20	mL	of	1	N	HCl	were	added	and	a	reflux	for	2	hrs	was	
done.	 Complete	 degradation	was	 followed	 and	 confirmed	 by	
the	 reported	 HPLC	 method	 [11].	 Subsequently,	 the	 solution	
was	 neutralized	 to	 pH	 =	 7±0.2	 by	 1.0	 N	 NaOH,	 evaporated	
nearly	to	dryness	under	vacuum,	cooled	to	room	temperature	
(25	°C),	then	quantitatively	transferred	with	methanol	to	a	50	
mL	measuring	 flask	 and	 completed	 to	 volume	with	 the	 same	
solvent.	 A	 working	 stock	 solution	 of	 the	 acid	 degradation	
products	 (0.08	 mg/mL)	 was	 prepared	 by	 transferring	 an	
accurate	 aliquot	 portion	 of	 the	 acid	 degradation	 products	
stock	solution	(1	mg/mL)	into	a	100	mL	volumetric	 flask	and	
diluted	with	methanol.		
	
	
2.5.	Procedures	
	
2.5.1.	Spectral	characteristics	
	
The	 absorption	 spectra	 of	 the	 intact	 and	 degraded	 SER	
samples	 were	 recorded	 over	 the	 range	 200‐400	 nm,	 using	
methanol	as	a	blank	(Figure	2).	
 
	
	
Figure	 2.	 Zero‐order	 spectra	 of	 pure	 sertaconazole	 (___)	 and	 its	 acid	
degradate	(‐	‐	‐),	each	of	40	µg/mL.	
	
2.5.2.	Construction	of	calibration	curves	for	1D	
spectrophotometric	method	
	
Accurately	 measured	 volumes	 of	 intact	 SER	 working	
solution	(0.08	mg/mL)	were	transferred	into	a	series	of	10	mL	
volumetric	 flasks	 and	 diluted	 to	 the	 mark	 with	 methanol	 to	
obtain	concentrations	 from	4	 to	64	µg/mL.	The	 1D	spectra	of	
each	solution	was	 recorded	using	Δλ	=	4	and	scaling	 factor	=	
100.	 Calibration	 curves	 were	 obtained	 by	 plotting	 the	 peak	
amplitudes	 of	 1D	 at	 290	 nm	 at	 which	 zero‐crossing	 of	 the	
degradation	products	was	observed	versus	the	corresponding	
drug	concentrations,	and	regression	equation	was	computed.	
	
2.5.3.	Construction	of	calibration	curves	of	1DD	
spectrophotometric	method	
	
Different	 aliquots	 of	 intact	 SER	 working	 solution	 (0.08	
mg/mL)	 were	 accurately	 transferred	 into	 a	 series	 of	 10	 mL	
volumetric	 flasks	 and	 diluted	 to	 the	 mark	 with	 methanol	 to	
obtain	 concentrations	 from	 4	 to	 64	 µg/mL.	 The	 absorption	
spectra	 of	 these	 solutions	 were	 divided	 by	 the	 absorption	
spectrum	 of	 4	 µg/mL	 of	 the	 acidic	 degradates	 (as	 a	 divisor).	
The	 obtained	 ratio	 spectra	 were	 then	 differentiated	 with	
respect	to	wavelength.	The	1DD	curves	were	recorded	at	Δλ	=	8	
and	scaling	factor	=	10.	The	peak	amplitudes	of	a	maximum	at	
λ	=	300	nm	and	of	a	 trough	at	λ	=	304	nm	were	recorded	for	
the	determination	of	SER	in	presence	of	 its	acidic	degradates.	
The	calibration	curves	representing	 the	relationship	between	
the	 measured	 amplitudes	 and	 the	 corresponding	 concent‐
rations	 of	 the	 drug	 were	 constructed	 and	 the	 regression	
equations	were	computed.	
	
2.5.4.	Construction	of	the	calibration	curve	of	the	HPLC	
method		
	
The	 chromatographic	 separation	 was	 carried	 out	 at	
ambient	 temperature	 on	 a	 ZORBAX‐ODS	 C18	 column	 (250	 ×	
4.6	 mm,	 i.d.),	 particle	 size	 (5	 μm),	 (Agilent	 Technologies,	
Waldbronn‐Germany),	 with	 isocratic	 elution	 at	 1.0	 mL/min	
using	the	mobile	phase;	methanol:formic	acid	(0.2%)	aqueous	
solution	(75:25,	v:v);	pH	=	3.5.	The	mobile	phase	was	filtered	
through	 a	 0.45	 μm	Millipore	 Corp.	 (Billerica,	MA)	membrane	
filter	and	degassed	for	about	15	min	in	an	ultrasonic	bath	prior	
to	use.	
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Figure	3.	Suggested	degradation	pathway	of	sertaconazole.	
	
	
	
	
Figure	4.	Mass	spectrum	of	the	acidic	degradation	product	I.	
	
	
To	 reach	 equilibrium,	 the	 analysis	 was	 usually	 started	
after	passage	of	50‐60	mL	mobile	phase.	
A	 series	of	working	solutions	containing	0.8	 to	40	µg/mL	
SER	and	10	µg/mL	clotrimazole	 (CZ)	 as	 an	 internal	 standard	
(IS)	were	prepared	by	serial	dilution	of	the	standard	working	
solution	 with	 the	 mobile	 phase.	 Then	 the	 solutions	 were	
sonicated	 for	 5	 minutes	 and	 filtered	 through	 a	 disposable	
syringe	 filter	 (0.45	 µm)	 before	 column	 injection.	 20	 µL	
Aliquots	of	each	solution	were	injected	in	triplicate	and	eluted	
with	 the	mobile	 phase.	 The	 eluted	 analytes	were	 detected	 at	
260	nm	with	a	sensitivity	of	0.001	absorbance	unit	 full	 scale.	
The	 average	 peak	 areas	 ratios	 were	 plotted	 versus	 the	
corresponding	concentrations	to	obtain	the	calibration	curves.	
Alternatively,	 the	 corresponding	 regression	 equation	 was	
derived.		
	
2.5.5.	Assay	of	laboratory	prepared	mixtures	
	
Different	 aliquot	 portions	 of	 the	 intact	 SER	 working	
solution	 (0.08	 mg/mL)	 were	 accurately	 transferred	 into	 a	
series	 of	 10	 mL	 measuring	 flasks,	 and	 mixed	 with	 variable	
portions	of	the	acid	degraded	standard	or	working	solutions	to	
prepare	 laboratory	 mixtures	 containing	 10‐90%	 of	 the	
degradation	 products.	 The	 volume	 was	 completed	 with	 the	
appropriate	 solvent	 for	 each	 procedure.	 The	 mixtures	 were	
analyzed	by	the	proposed	methods	and	the	concentrations	of	
the	 intact	 drug	 were	 calculated	 from	 the	 corresponding	
regression	equations.	
	
2.5.6.	Application	to	pharmaceutical	products	
	
Accurate	 amount	 of	 Dermofix®	 powder	 corresponding	 to	
50	mg	SER	was	transferred	into	50	mL	volumetric	flask.	About	
30	mL	of	methanol	was	added	and	followed	by	sonication	for	
15	 min.	 The	 solutions	 were	 completed	 to	 the	 volume	 with	
methanol,	mixed	well	and	filtered.		
An	 accurately	 weighed	 amount	 of	 Dermofix®	 cream	
corresponding	 to	 50	mg	 SER	was	 transferred	 into	 a	 100	mL	
beaker.	 About	 20	 mL	 of	 methanol	 was	 added	 followed	 by	
sonication	in	an	ultrasonic	bath	for	15	min.	The	solutions	were	
stirred	for	5	min	then	cooled	at	refrigerator.	This	process	was	
repeated	 twice.	 Then,	 the	 supernatant	 phase	 was	 quantita‐
tively	 transferred	 to	 a	 50	mL	 volumetric	 flask	 through	 filter	
paper	 and	 completed	with	methanol.	 Suitable	 dilutions	were	
done	using	methanol	for	the	spectrophotometric	methods	and	
the	suggested	mobile	phase	for	the	HPLC	one.	
The	proposed	methods	were	applied	for	the	analysis	of	the	
pharmaceutical	 preparation	 solutions	 using	 the	 procedures	
mentioned	before.	The	concentrations	of	SER	were	calculated	
from	the	corresponding	regression	equations.	
	
3.	Results	and	discussion	
	
3.1.	Identification	of	the	degradation	product	
	
Sertaconazole	is	completely	hydrolyzed	with	1	M	HCl	after	
reflux	 of	 2	 hrs,	 through	 the	 splitting	 of	 the	 ether	 linkage	
[12,13].	The	expected	major	degradation	products	I	and	II	are	
obtained	 according	 to	 the	 suggested	 mechanism	 for	 acid	
degradation	 process	 of	 SER,	 and	 the	 major	 degradation	
products	suggested	in	acidic	conditions	are	N‐(2‐(2,4‐dichloro‐
phenyl)‐2‐hydroxy)ethylimidazole	(I)	and	7‐chloro‐3‐hydroxy	
methyl	benzothiophene	(II),	as	presented	in	Figure	3.	
The	 assignment	 of	 the	 degradation	 pathway	 and	 the	
suggested	 structures	 of	 the	 degradation	 products	 were	
confirmed	 by	 mass	 spectral	 data.	 The	 mass	 spectrum	 of	
degradation	product	I	was	characterized	by	the	appearance	of	
the	 molecular	 ion	 peak	 at	 256	 m/z	 which	 confirms	 the	
molecular	 weight	 of	 the	 suggested	 degradation	 product	 I,	
Figure	4.		
	
3.2.	Method	development	and	optimization	
	
The	quantitative	determination	of	 SER	 in	 the	presence	of	
its	 acidic	 degradation	 products	 by	 conventional	 zero	 order	
spectrophotometry	 is	 completely	 hindered	 due	 to	 the	 strong	
spectral	overlap	throughout	the	wavelength	range	(Figure	2).	
The	 focus	 of	 the	 present	 work	 is	 to	 develop	 accurate,	
specific,	 reproducible	 and	 sensitive	 stability	 indicating	
methods	 for	 the	 determination	 of	 SER	 in	 pure	 form,	 in	
pharmaceutical	 formulations	 and	 in	 the	 presence	 of	 acidic	
degradates.	
	
3.2.1.	Derivative	spectrophotometry	
	
Derivative	spectrophotometry	is	considered	to	be	an	ideal	
stability	 indicating	method	 that	 quantifies	 the	 standard	 drug	
alone	 and	 also	 resolves	 its	 degradation	products	 as	 reported	
for	 antipsychotic	 drug,	 olanzapine	 [14].	 A	 rapid,	 simple	 and	
low	cost	spectrophotometric	method	based	on	measuring	the	
peak	amplitude	of	1D	at	290	nm	(Figure	5)	was	developed	for	
determination	 of	 SER	 in	 presence	 of	 its	 acidic	 degradates	
(Corresponding	to	zero	crossing	of	the	degradates).	
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Table	1.	Regression	and	assay	validation	parameters	for	determination	of	pure	samples	of	SER	by	the	proposed	methods.	
Parameter	 1D	method
290	nm	
1DD	method HPLC	method
300 nm 304 nm
Linearity	range,	μg/mL	 4‐64 4‐64 4‐64 0.8‐40		
Slope	±	SD	 0.0435±0.0035 0.0384±0.0025 0.0465±0.0055	 0.0251±0.0091
Intercept	±	SD	 0.0292±0.055 0.0449±0.0012 0.0827±0.0085	 0.0003±0.0115
Correlation	coefficient	(r)	 0.9999	 0.9999	 0.9999	 0.9999	
Mean	recovery	%	±	SD	 99.77±0.781	 99.98±0.720	 100.46±0.640	 	99.65±0.630		
LOD	a	(μg/mL)	 1.16 1.29 1.06 0.132	
LOQ	a	(μg	mL)	 3.45	 3.91	 3.23	 0.4	
Precision	(RSD	%)	 	 	 	 	
Repeatability	b	 0.375‐0.758‐0.795 0.475‐0.518‐0.675 1.024‐0.757‐0.535	 1.135‐0.564‐1.226
Intermediate	precision	b	 0.998‐0.458‐0.708 1.315‐1.550‐0.597 1.852‐1.540‐0.776	 0.995‐0.448‐1.205
Robustness	data	c	 	 	
Peak	amplitude	in	1D	method	
At	290.2	nm	
At	289.8	nm		
	
99.25±0.825	
99.75±1.225	
	
Peak	amplitude	in	1DD	method		
At	300±0.2	nm		
At	304±0.2	nm	
	 	
99.85±0.998	
	
	
	
100.05±1.245	
		
Methanol:0.2%	formic	acid	(75±1:25±1,	v:v)	
pH	=	3.5±0.05	
	 	 100.55±0.556	
99.98±0.458
	
Flow	rate	1±0.2	mL/min	 	 99.58±0.878 	
a	Limits	of	detection	and	quantitation	are	determined	via	calculations:	LOD	=	(SD	of	the	response/slope)	×	3.3.	LOQ	=	(SD	of	the	response/slope)	×	10.	
b	The	intra‐day	and	inter‐day	relative	standard	deviations	of	8,	16	and	32	μg/mL	SER;	each	of	triplicate	analysis	
c	Mean	recovery	%±RSD	(n	=	5).	
	
	
Table	2.	Determination	of	 SER	 in	 the	 laboratory	prepared	 (L.P.)	mixtures	with	 its	 acidic	 degradation	products	 and	 in	dosage	 forms	 and	 the	application	 of	
standard	addition	technique	by	the	proposed	methods.	
Samples	 1D‐method	a	
290	nm	
1DD‐method	a	 HPLC‐method	a	
300 nm 304 nm	
Laboratory	prepared	mixtures,	10	to	90%	degradation,	(n = 5)	b 99.96±0.585 100.06±0.900 100.31±0.759	 100.84±0.246
Dermofix®	cream,	Batch	No.	030409,	(n	=	4)	b	 100.28±0.839 99.88±1.093 99.91±1.040	 99.92±0.721
Standard	addition	(n	=	4)	b	 99.83±1.006 100.25±1.317 100.94±1.096	 100.30±0.857
Dermofix	®	powder,	Batch	No.	0080909,	(n	=	4)	b	 99.21±0.419 100.56±0.735 100.37±1.121	 100.05±0.325
Standard	addition	(n	=	4)	b	 100.18±0.636 100.03±1.125 100.17±0.865	 99.67±0.479
a	Recovery±RSD.	
b	Sets	each	of	3	replicates.	
	
	
In	 order	 to	 optimize	 1D	method,	 different	 smoothing	 and	
scaling	 factors	were	 tested,	where	a	 smoothing	 factor	Δλ	=	4	
and	scaling	factor	=	100	showed	a	suitable	signal	to	noise	ratio	
and	 the	 spectra	 showed	 good	 resolutions.	 The	 regression	
equations	were	computed	(Table	1).	
 
	
	
Figure	5.	First	 derivative	 spectra	 of	 pure	 sertaconazole	 (___)	 and	 its	 acid	
degradate	(‐	‐	‐	‐),	each	of	40	µg/mL.	
 
The	proposed	method	is	valid	for	the	determination	of	SER	
with	good	selectivity	without	interference	of	up	to	90%	of	its	
acidic	degradates	over	concentration	 range	 from	4‐64	µg/mL	
(Table	2).	
	
3.2.2.	1	DD	method	
	
In	order	to	improve	the	selectivity	of	the	analysis	of	SER	in	
presence	 of	 its	 acidic	 degradates	 the	 1DD	 method	 was	
established.	 The	 main	 advantage	 of	 the	 method	 is	 that	 the	
whole	 spectrum	 of	 interfering	 substance	 is	 cancelled.	
Accordingly,	 the	 critical	 measurements	 at	 the	 selected	
wavelengths	are	not	applied	anymore.		
In	order	to	optimize	1DD	method	for	determination	of	SER	
in	presence	of	 its	degradation	products,	it	 is	necessary	to	test	
the	 influence	 of	 the	 variables:	 divisor	 concentration,	
smoothing	and	scaling	 factors.	 Several	divisor	 concentrations	
of	 the	 acidic	 degradates	 were	 tried,	 the	 best	 results	 was	
obtained	 when	 using	 4	 µg/mL	 of	 degradates	 as	 a	 divisor.	
Different	 smoothing	 and	 scaling	 factors	 were	 also	 tested	
where	a	 smoothing	 factor	Δλ	=	8	nm,	 and	scaling	 factor	=	10	
were	 suitable	 to	 enlarge	 the	 signals	 of	 SER	 to	 facilitate	 its	
measurement	and	to	diminish	error	in	reading	the	signal.	1DD	
values	 showed	 good	 linearity	 and	 reproducibility	 at	 300	 and	
304	 nm	 without	 interference	 from	 its	 acidic	 degradates	
(Figure	6).	Linearity	of	the	peak	amplitudes	of	the	1DD	curves	
at	 both	wavelengths	was	 obtained	 in	 range	 4‐64	 µg/mL	 and	
the	regression	equations	were	computed	(Table	1).	
	
3.2.3.	HPLC	method	
	
The	 developed	 HPLC	 method	 has	 been	 applied	 for	 the	
separation	 and	 determination	 of	 SER	 in	 the	 presence	 of	 its	
acidic	 degradation	 products.	 To	 optimize	 the	 HPLC	 assay	
parameters,	 the	 mobile	 phase	 composition	 was	 studied.	 A	
satisfactory	 separation	 was	 obtained	 with	 a	 mobile	 phase	
consisting	 of	 methanol:formic	 acid	 (0.2%)	 aqueous	 solution	
(75:25,	v:v);	pH	=	3.5	 at	an	ambient	 temperature	with	a	 flow	
rate	 of	 1.0	mL/min,	 followed	 by	 UV	 detection	 at	 260	nm.	
Complete	 baseline	 separation	 of	 SER	 and	 its	 degradation	
products	was	noticed	in	Figure	7.		
The	average	retention	times	were	found	to	be	3.8±0.1	min	
for	intact	SER	and	1.4±0.2	for	its	degradates	for	10	replicates.	
All	peak	parameters	of	resolution	efficiency	were	calculated	to	
ensure	 that	 the	 system	 is	 working	 correctly	 during	 the	
analysis.	
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Table	3.	Parameters	of	system	suitability	of	the	developed	chromatographic	method	for	the	determination	of	SER	in	presence	of	its	degradation	products.	
Parameters	 HPLC	Method	 Reference	values	[15,16]	
Resolution	(Rs)	 3.69	 >	1.5
Selectivity	(α)	 6.94	 >1
Tailing	factor	(T)	 1.07	 ≈1
Capacity	factor	(K΄)	 3.75	 1‐10	acceptable
Column	efficiency	(N)	 924.16	 Increase	with	efficiency	of	the	separation	
HETP	*	 0.27	 The	smaller	the	value	the	higher	the	column	efficiency	
*	Height	equivalent	to	theoretical	plate.	
 
Overall	system	suitability	testing	was	done	to	determine	if	
the	 operating	 system	 was	 performing	 properly	 [15,16],	 and	
the	results	obtained	are	listed	in	Table	3.	
	
	
	
Figure	 6.	 1D‐Ratio	 spectra	 of	 different	 concentrations	 (4‐64	 µg/mL)	 of	
sertaconazole	using	a	spectrum	of	4	µg/mL	of	its	degradate	as	a	divisor.	
 
 
	
	
Figure	7.	Typical	 HPLC	 chromatogram	 of	 laboratory	 prepared	mixture	 of	
intact	SER	and	its	acid	degradate	(each	of	20	µg/mL)	using	clotrimazole	(10	
µg/mL)	as	an	internal	standard.	
	
3.3.	Method	validation	
	
3.3.1.	Linearity	and	range	
	
Calibration	 curves	 for	 the	 proposed	 methods	 were	
constructed	 and	 evaluated	 by	 their	 correlation	 coefficients.	
Linearity	of	spectrophotometric	methods	was	obtained	 in	the	
concentration	 range	 of	 4‐64	 μg/mL	of	 SER	 with	 mean	
percentage	 recoveries	 of	 99.77±0.781	 (n	=	8)	 for	 1D	method.	
While	 for	1DD	method	 the	mean	 percentage	 recoveries	 were	
found	to	be	99.98±0.720	at	300	nm	and	100.46±0.640	at	304	
nm	 (n	=	8).	 In	 the	HPLC	method,	 the	 linearity	 of	 the	detector	
response	of	SER	was	determined	by	plotting	peak	area	ratios	
versus	concentrations,	and	 linear	correlation	was	obtained	in	
range	 of	 0.8‐40	 μg/mL	 with	 mean	 percentage	 recoveries	 of	
99.65±0.630	(n	=	7).	
The	 regression	 equations	 parameters	 of	 the	 all	 proposed	
methods	were	computed	and	given	 in	Table	1	which	shows	a	
good	linear	relationship	for	the	suggested	methods	as	revealed	
by	 the	 correlation	 coefficients.	 Descriptive	 statistics	 of	 the	
regression	 showed	 low	 values	 of	 the	 standard	 deviation	 of	
intercept	 and	 slope	 which	 revealed	 high	 accuracy	 with	
minimum	 deviations	 and	 low	 scattering	 of	 the	 calibration	
points	[17].	
 
3.3.2.	Accuracy	
	
The	 accuracy	 of	 the	 suggested	methods	was	 assessed	 by	
applying	 standard	 addition	 technique	 by	 spiking	 different	
amounts	 of	pure	 sertaconazole	 samples	 to	 a	 certain	 concent‐
ration	of	the	dosage	forms.	The	mean	recoveries	of	the	added	
drug	 were	 calculated	 and	 illustrated	 in	 Table	 2.	 No	 inter‐
ference	 due	 to	 excipients	 was	 observed	 as	 shown	 from	 the	
obtained	results.	
	
3.3.3.	Precision	
	
Repeatability	was	 evaluated	by	 assaying	 freshly	prepared	
solutions	 in	 triplicate	on	 the	same	day	having	concentrations	
of	8,	16	and	32	μg/mL	of	SER	by	the	suggested	spectrophoto‐
metric	 and	 HPLC	 methods.	 Intermediate	 precision	was	
assessed	by	analyzing	freshly	prepared	solutions	of	the	above	
mentioned	 concentrations	 in	 triplicate	 in	 three	 successive	
days.	The	%	Recovery	and	%RSD	were	then	calculated	(Table	
1).	
	
3.3.4.	Specificity	
	
In	 order	 to	 test	 the	 validity	 and	 applicability	 of	 the	
proposed	 methods	 as	 stability‐indicating	 ones,	 recovery	
studies	 were	 performed	 by	 analyzing	 synthetic	 mixtures	 of	
different	ratios	of	the	intact	drug	and	its	degradation	product.	
Results	 in	Table	 2	 confirm	 the	 validity	 and	 specificity	 of	 the	
proposed	methods.	
	
3.3.5.	Detection	and	quantitation	limits	(sensitivity)	
	
According	 to	 International	 Conference	 on	 Harmonisation	
[ICH]	 recommendations	 [18],	 the	 approach	 based	 on	 the	
standard	deviation	values	[S.D.]	of	the	response	and	the	slope	
was	used	for	determining	the	detection	and	quantitation	limits	
(LOD,	 LOQ).	 The	 theoretical	 values	 were	 assessed	 and	 given	
in	Table	1.	
	
3.3.6.	Application	to	pharmaceutical	formulations	
	
The	 suggested	methods	were	 successfully	 applied	 for	 the	
determination	 of	 SER	 in	 creams	 and	 powered	 forms.	 The	
results	 shown	 in	 Table	 2	were	 satisfactory	 and	 with	 good	
agreement	with	the	labeled	amounts.	
	
3.3.7.	Robustness	
	
The	 robustness	 of	 the	 developed	methods	 was	 examined	 by	
detecting	the	effect	of	small	but	deliberate	variations	of	some	
of	 the	 most	 important	 procedure	 parameters	 such	 as	
wavelength	of	the	peak	amplitudes	in	1D	and	1DD	method	and	
percentage	 organic	 strength;	 pH	 and	 flow	 rate	 of	 the	mobile	
phase	 in	 the	 HPLC	 method.	 None	 of	 these	 variables	
significantly	 affected	 the	 assay	 of	 SER	 and	 the	 proposed	
methods	could	be	considered	robust	(Table	2).	
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Table	4.	Statistical	analysis	of	the	proposed	methods	and	the	official	method	of	Sertaconazole	in	the	pure	powder	form.	
Parameter	 1D	method	 1DD	method	 HPLC	method	 Official	method	[4]	
300	nm 304 nm
Mean	 99.77	 99.98	 100.46 99.65 100.52	
SD	 0.781	 0.720	 0.640 0.630 0.427	
n	 8	 8	 8 7 5	
Variance	 0.610	 0.518	 0.410 0.397 0.182	
Student’s	t‐test	 1.506	(2.201)	*	 1.118	(2.201)	* 0.130	(2.201)	* 1.835	(2.228)	* 	
F‐test	 3.352	(6.09)	*	 2.846	(6.09)	* 2.253	(6.09)	* 2.181	(6.16)	* 	
*	Figures	in	parenthesis	are	corresponding	theoretical	t‐	and	F‐values	at	p	=	0.05.	
 
3.3.8.	Statistical	comparison	to	the	official	method	
	
Statistical	analysis	of	the	results	obtained	by	the	suggested	
procedures	 and	 the	 official	 non	 aqueous	 method	 [4]	was	
carried	 out.	 Table	 4	shows	 that	 the	 calculated	t‐	 and	F‐values	
were	 less	 than	 the	 theoretical	 ones	 [19],	 indicating	 no	
significant	differences	between	 the	proposed	procedures	 and	
the	reported	one.	
	
4.	Conclusion	
	
Simple	 newly	 developed	1D,	 1DD,	 and	 isocratic	 HPLC	
methods	are	presented	as	stability	indicating	methods	for	the	
determination	 of	 sertaconazole	 in	 the	 presence	 of	 its	 acidic	
degradation	 products.	 From	 the	 previous	 discussion	 and	
results	 obtained	 in	 this	work,	 we	 can	 conclude	with	 95%	 of	
confidence	 that	 the	 three	 suggested	 methods	 are	 simple,	
sensitive,	selective	and	can	be	applied	for	quality	control	and	
routine	analysis	of	sertaconazole	in	pure	form,	in	the	presence	
of	 its	acidic	degradation	products	and	in	the	available	dosage	
forms	 without	 any	 interference	 from	 the	 excipients.	 In	
addition,	 the	 suggested	HPLC	method	has	 an	 advantage	 over	
the	 reference	 one	 [8]	of	 being	 more	 sensitive	 and	 showing	
short	time	of	analysis	as	the	overall	run	time	doesn’t	exceed	5	
minutes.	 It	 offers	 complete	 separation	 of	 the	 drug	 and	 its	
degradation	 products	 which	 gives	 the	 opportunity	 for	 drug	
quantitation	and	purity	assessment	in	quality	control	labs.	
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